Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02337062 |
|
Recruitment Status :
Completed
First Posted : January 13, 2015
Results First Posted : August 4, 2017
Last Update Posted : March 20, 2019
|
Sponsor:
Acacia Pharma Ltd
Information provided by (Responsible Party):
Acacia Pharma Ltd
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| PONV | Drug: APD421 Drug: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1147 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients |
| Study Start Date : | February 2015 |
| Actual Primary Completion Date : | September 2015 |
| Actual Study Completion Date : | September 2015 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Nausea and Vomiting
| Arm | Intervention/treatment |
|---|---|
|
Experimental: APD421 + standard anti-emetic
Single dose of IV APD421
|
Drug: APD421 |
|
Placebo Comparator: Placebo + standard anti-emetic
Single dose of IV placebo
|
Drug: Placebo |
Primary Outcome Measures :
- Number of Participants With Complete Response [ Time Frame: 24 hours after the end of surgery ]Complete response defined as no emesis and no use of rescue medication in the 24 hour period after end of surgery (defined as wound closure)
Secondary Outcome Measures :
- Number of Participants With Emesis [ Time Frame: 24 hours after the end of surgery ]Emesis is defined as vomiting (production of even the smallest amount of stomach contents) or retching (muscular movements of vomiting but without expulsion of stomach contents, usually because of an empty stomach)
- Number of Participants Receiving Rescue Medication [ Time Frame: 24 hours after the end of surgery ]Rescue medication defined as an antiemetic (or other medication) given with the intention of relieving nausea and/or emesis, or any incidental use of a drug known to have antiemetic potential
- Number of Participants With Any Nausea [ Time Frame: 24 hours after the end of surgery ]Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. "Any nausea" means a score ≥ 1.
- Number of Participants With Significant Nausea [ Time Frame: 24 hours after end of surgery ]Nausea (defined as the desire to vomit without the presence of expulsive muscular movements) measured on a 0-10 verbal response scale, where 0=no nausea at all and 10=the worst nausea imaginable. "Significant nausea" means a score ≥ 4.
- Time to First Violation of Criteria for PONV [ Time Frame: 24 hours after end of surgery ]Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female patients ≥ 18 years of age
- Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure
- Patients with at least 3 "Apfel" risk factors for PONV
Exclusion Criteria:
- Patients scheduled to undergo transplant surgery
- Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block
- Patients who are expected to remain ventilated for a period after surgery
- Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02337062
Locations
Show 25 study locations
Sponsors and Collaborators
Acacia Pharma Ltd
Investigators
| Principal Investigator: | Peter Kranke, MD | Würzburg University Hospitals |
| Responsible Party: | Acacia Pharma Ltd |
| ClinicalTrials.gov Identifier: | NCT02337062 |
| Other Study ID Numbers: |
DP10017 |
| First Posted: | January 13, 2015 Key Record Dates |
| Results First Posted: | August 4, 2017 |
| Last Update Posted: | March 20, 2019 |
| Last Verified: | March 2019 |